Business & Regulation

Ireland can boast of many success stories when it comes to biopharma investment. Here, Barry Heavey from IDA takes us on a tour of recent investments and explains why talent and training are key.

The UK votes to leave the European Union: what happens next, and what are the implications for pharma?

When an industry grows rapidly, innovative approaches are required to ensure sustainable growth. Here, we speak to leaders at Ireland’s National Institute for Bioprocess Research and Training – NIBRT – to find out how a focus on talent, training and technology is changing the face of the field.

Packaging components can leach into drug products and become foreign impurities. Guidelines exist for the testing of drug products for elemental impurities, but how are these applied to elemental impurities derived from drug product packaging?

Will future drugs in Europe be priced based on therapeutic outcomes?

Will expanding the Priority Review Voucher scheme defeat its original purpose?

How difficult is it to develop a new drug? Statistics have the answer

The EMA says it will review its standards for first-in-human trials

A survey-based report highlights wildly inaccurate drug demand projections

Astronomers Chris Leigh and Mike Merrifield debate how a potential Brexit might impact UK science